Press Releases from 2012

Reinach, Switzerland, 20 December 2012 – Evolva Holding SA (SIX: EVE) today announces it has had a positive meeting with the German regulatory authority BfArM regarding the further clinical steps for EV-077.

Evolva gains first on-market product, consolidates technology strengths

Associated reprioritisation of Evolva’s development portfolio

Reinach, Switzerland, 26 September 2012 – Evolva Holding SA (SIX: EVE) today announced that Roquette Frères SA (Roquette) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2012.

Reinach, Switzerland, 10 September 2012 - Evolva Holding SA (SIX: EVE) presented extensive preclinical data on EV-035 at ICAAC, the world’s premier international conference on antimicrobial agents and infectious diseases.

Reinach, Switzerland, 29 August 2012 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 30 June 2012. The condensed accounts are available on Evolva’s website.

Reinach, Switzerland, 28 August 2012 - Evolva Holding SA (SIX: EVE) today announces further data for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids. 16 patients received EV-077 and 16 patients received placebo.

Further data to be presented at ESC Congress 2012

Reinach, Switzerland, 17 August 2012 – Evolva Holding SA (SIX: EVE) today announced top-line results for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids.

Reinach, Switzerland, 21 June 2012 – Evolva Holding SA (SIX: EVE) today announced that International Flavors & Fragrances Inc. (IFF) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2011.

Reinach, Switzerland, 9 May 2012 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.

Contact Information

Evolva SA
Duggingerstrasse 23
CH-4153 Reinach
Switzerland
Tel: +41 61 485 2000
Fax: +41 61 485 2001
Evolva A/S
Lersoe Parkallé 42-44
DK-2100 Copenhagen OE
Denmark
Tel: +45 35 200 230
Fax: +45 35 200 231
Evolva Biotech Private Limited
401 - 405, 4th Floor
Ticel Bio Park Ltd
Taramani Road, Taramani
Chennai 600 113
Tamil Nadu, India
Tel: +91 44 4297 1050
Fax: +91 44 4297 1060
Evolva, Inc. (Evolva USA)
2440 Embarcadero Way
Palo Alto
CA 94303
USA
Tel: +1 650 856 2436
Fax: +1 650 856 7950

General Enquiries: info@evolva.com • Business Enquiries: busdev@evolva.com • India Enquiries: info_india@evolva.com